NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis $0.76 -0.03 (-3.23%) Closing price 04:00 PM EasternExtended Trading$0.77 +0.01 (+0.85%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About MIRA Pharmaceuticals Stock (NASDAQ:MIRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MIRA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.76▼$0.7950-Day Range$0.61▼$1.0152-Week Range$0.60▼$2.45Volume40,249 shsAverage Volume97,453 shsMarket Capitalization$32.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. Read More MIRA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreMIRA MarketRank™: MIRA Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 796th out of 909 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingMIRA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMIRA Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about MIRA Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of MIRA Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MIRA Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMIRA Pharmaceuticals has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MIRA Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.61% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 2.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently decreased by 19.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMIRA Pharmaceuticals does not currently pay a dividend.Dividend GrowthMIRA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentMIRA Pharmaceuticals has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for MIRA Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.89% of the stock of MIRA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.16% of the stock of MIRA Pharmaceuticals is held by institutions.Read more about MIRA Pharmaceuticals' insider trading history. Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIRA Stock News HeadlinesMIRA Reports Positive 7-Day Dog Study Results for SKNY-1August 6, 2026 | finance.yahoo.comMIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling StudiesJuly 30, 2026 | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.August 18 at 1:00 AM | Porter & Company (Ad)Mira Pharmaceuticals stock gains on Phase 1 trial resultsMay 14, 2026 | investing.comWhat's going on with MIRA Pharma stock Tuesday?March 24, 2026 | msn.comMIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trialMarch 5, 2026 | yahoo.comMIRA Pharmaceuticals (MIRA) Price Target Decreased by 83.10% to 3.06October 29, 2025 | msn.comMira Pharmaceuticals announces preclinical data on oral Mira-55October 17, 2025 | msn.comSee More Headlines MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed this year? MIRA Pharmaceuticals' stock was trading at $1.51 at the beginning of 2026. Since then, MIRA shares have decreased by 49.4% and is now trading at $0.7645. How were MIRA Pharmaceuticals' earnings last quarter? MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter. When did MIRA Pharmaceuticals IPO? MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering (IPO) on Wednesday, August 2nd 2023. The company issued 1,275,000 shares at a price of $6.00-$8.00 per share. Who are MIRA Pharmaceuticals' major shareholders? MIRA Pharmaceuticals' top institutional investors include BlackRock Inc. (0.58%). Insiders that own company stock include Erez Aminov and Brian Patrick Mcnulty. View institutional ownership trends. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MIRA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Alamos Gold (AGI) and GeoVax Labs (GOVX). Company Calendar Last Earnings8/12/2026Today8/18/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 MIRA's financial health is in the Yellow zone, according to TradeSmith. MIRA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CIK1904286 Webmirapharmaceuticals.com Phone737-289-0835FaxN/AEmployees2Year Founded1978Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.95% Return on Assets-104.18% Debt Debt-to-Equity RatioN/A Current Ratio200.08 Quick Ratio200.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book3.06Miscellaneous Outstanding Shares42,020,000Free Float33,664,000Market Cap$32.12 million OptionableNot Optionable Beta1.54 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MIRA) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredI’m sharing my top day trading secrets for freeA 30-year trading veteran who managed multi-million-dollar hedge funds and wealth for one of the world's riche...The TradingPub | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
